Mutant p62^{P392L} Stimulation of Osteoclast Differentiation in Paget's Disease of Bone

Kumaran Sundaram, Srinivasan Shanmugarajan, D. Sudhaker Rao, and Sakamuri V. Reddy

Charles P. Darby Children's Research Institute (K.S., S.S., S.V.R.), Medical University of South Carolina, Charleston, South Carolina 29425; and Henry Ford Hospital (D.S.R.), Detroit, Michigan 48202

Paget's disease of the bone (PDB) is an autosomal dominant trait with genetic heterogeneity, characterized by abnormal osteoclastogenesis. Sequestosome 1 (p62) is a scaffold protein that plays an important role in receptor activator of nuclear factor κB (RANK) signaling essential for osteoclast (OCL) differentiation. p62^{P392L} mutation in the ubiquitin-associated (UBA) domain is widely associated with PDB; however, the mechanisms by which p62^{P392L} stimulate OCL differentiation in PDB are not completely understood. Deubiquitinating enzyme cylindromatosis (CYLD) has been shown to negatively regulate RANK ligand-RANK signaling essential for OCL differentiation. Here, we report that CYLD binds with the p62 wild-type (p62^{WT}), non-UBA mutant (p62^{A381V}) but not with the UBA mutant (p62^{P392L}) in OCL progenitor cells. Also, p62^{P392L} induces expression of c-Fos (2.8-fold) and nuclear factor of activated T cells c1 (6.0-fold) transcription factors critical for OCL differentiation. Furthermore, p62^{P392L} expression results in accumulation of polyubiquitinated TNF receptor-associated factor (TRAF)6 and elevated levels of phospho-IκB during OCL differentiation. Retroviral transduction of p62^{P392L}/CYLD short hairpin RNA significantly increased TRAP positive multinucleated OCL formation/bone resorption activity in mouse bone marrow cultures. Thus, the p62^{P392L} mutation abolished CYLD interaction and enhanced OCL development/bone resorption activity in PDB. (*Endocrinology* 152: 4180–4189, 2011)

Paget's disease of bone (PDB) is a chronic focal skeletal disorder that affects 2–3% of the population over the age of 60 yr. PDB is inherited as an autosomal dominant trait with genetic heterogeneity and characterized by highly localized areas of bone turnover with increased osteoclast (OCL) activity followed by an exaggerated osteoblast response (1). OCL in PDB contain paramyxoviral-nuclear inclusions and nucleocapsid transcripts (2). The nuclear inclusions were present in 20–40% of OCL in all patients with PDB (3). Furthermore, expressions of measles virus nucleocapsid (MVNP) transcripts have been detected in approximately 80% of bone marrow samples from patients with PDB (4). Recently, Merchant *et al.* (5) have found MVNP expression in pagetic bone and pagetic osteosarcomas. Previously, canine distemper virus nucleo-

capsid transcripts were also detected in pagetic bone samples (6). However, other workers have been unable to detect expression of paramyxoviral transcripts in PDB (7, 8). Sequestosome 1 (p62) (also known as SQSTM1) is a multifunctional ubiquitin-binding protein, which plays an important role in cell signaling, receptor internalization, and protein turnover (9). Recurrent mutations in p62 ubiquitin-associated (UBA) domain have been identified in about 25% of familial and less than 10% of sporadic cases; however, the P392L amino acid substitution being the most common in PDB (10). Furthermore, a mutation in p62 exon-7 (K378X), which introduces a premature stop codon and thus eliminates entire UBA domain, has been reported (11). Najat *et al.* (12) have also identified a non-UBA domain mutation, p62^{A381V} associated with PDB.

Abbreviations: AP-1, Activator protein 1; CYLD, cylindromatosis; EV, empty vector; FCS, fetal calf serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HA, hemagglutinin; K63, lysine-63; M-CSF, macrophage colony-stimulating factor; MVNP, measles virus nucleocapsid; NFATc1, nuclear factor of activated T cells c1; NF-κB, nuclear factor κB; OCL, osteoclast; p62, sequestosome 1; PDB, Paget's disease of bone; RANK, receptor activator of NF-κB; RANKL, RANK ligand; shRNA, short hairpin RNA; TRAF, TNF receptor-associated factor; TRAP, tartrate-resistant acid phosphatase; UBA, ubiquitin associated.

p62 has been shown to physically associate with TNF receptor-associated factor (TRAF)6 and involved in receptor activator of nuclear factor κB (NF-κB) (RANK) signaling critical for OCL differentiation (13). p62 is a scaffold protein that mediates RANK ligand (RANKL) signaling by activating transcription factors such as NF-κB and activator protein 1 (AP-1), which induces the nuclear factor of activated T cells (NFATc1) transcription factor expression essential for osteoclastogenesis (14–16). p62 knockout mice have impaired osteoclastogenesis in response to parathyroid hormone-related peptide (13). It has been shown that p62 mutant (p62^{P392L}) transgenic mice have increased OCL formation but do not develop focal osteolytic lesions with the characteristics of PDB (17). In contrast, recently, p62 UBA domain mutation (p62^{P394L}) has been shown to be sufficient to cause a Paget's disease-like disorder in mice (18). Also, truncation of the p62 UBA domain causes aberrant RANK signaling and increased osteoclastogenesis in RAW 264.7 cell cultures (19). Recently, p62^{P392L} mutation has been shown to alter RANKL signaling and induces activation of human OCL (20). However, the molecular mechanisms by which p62^{P392L} stimulates OCL differentiation in PDB are not completely understood.

Pridgeon *et al.* (21), using an *in vitro* expression cloning approach, identified several proteins that interact with the p62 UBA domain. The tumor suppressor cylindromatosis (CYLD) gene was first identified in human affected with familial CYLD, a genetic syndrome in which numerous benign tumors of skin develop, principally on the head and neck region. The disease is inherited in an autosomal manner and is caused by germline mutations in the CYLD gene on chromosome 16q12-q13, which predicts truncation or absence of the encoded protein (22). CYLD protein has been shown to physically interact with p62, and it negatively regulates osteoclastogenesis (23). CYLD is a deubiquitinase that removes the ubiquitin chain from several proteins, particularly TRAF2, TRAF6, and NF-κB essential modulator, and inactivates NF-κB signaling (24–26). The deubiquitination activity of CYLD is highly specific for proteins at lysine-63 (K63)-linked ubiquitin chains in substrate but has been shown to act on K48-linked polyubiquitin chains (27). Polyubiquitination of target protein at K63 influences protein-protein interactions, which play an important role in cell signaling, and ubiquitination at K48 directs to proteosomal degradation via ubiquitin-proteosomal pathway (28). Here, we report that the p62 UBA mutant (p62^{P392L}) abolished the interaction with CYLD, which implicates a potential role in enhanced OCL development in PDB.

Materials and Methods

Reagents and antibodies

Cell culture and DNA transfection reagents were purchased from Invitrogen Corp. (Carlsbad, CA). RANKL and macrophage colony-stimulating factor (M-CSF) were obtained from R&D Systems, Inc. (Minneapolis, MN). Rabbit-anti-CYLD antibody was purchased from Abcam (Cambridge, MA). Rabbit-anti-NFATc1, anti-c-Fos, antihemagglutinin (HA) tag, and peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). pNFAT, pNF-κB, and pAP-1-Luc cis-reporter plasmids were obtained from Stratagene (La Jolla, CA). SuperSignal enhanced chemiluminescence reagent was obtained from Amersham Bioscience (Piscataway, NJ), and nitrocellulose membranes were purchased from Millipore (Bedford, MA). A luciferase reporter assay system was obtained from Promega (Madison, WI).

p62 mutagenesis

A plasmid (pcDNA3-HA-p62) containing the full-length human p62 cDNA (>85% homologous to murine p62) was kindly provided by Jorge Moscat (Sanford-Burnham Medical Research Institute, La Jolla, CA), and the P392L mutation in UBA domain (exon-8) and A381V in non-UBA domain (exon-7) were introduced by site-directed mutagenesis using QuikChange II XL Site-Directed Mutagenesis kit (Stratagene, Inc., La Jolla, CA) as described earlier (29). The mutagenized p62 cDNA was sequence verified for correct introduction of P392L and A381V mutations (Fig. 1A).

p62 and CYLD short hairpin RNA (shRNA) retroviral expression

The p62^{WT} and mutant cDNA were excised from the pcDNA3-HA-p62 plasmids by digestion with *Eco*RI and subcloned into the pLXSN retroviral vector (Clontech Laboratories, Inc., Palo Alto, CA). The resulting plasmid construct transcribes p62 mRNA expression under the control of 5' long terminal repeat viral promoter elements. The recombinant p62 constructs and CYLD shRNA retroviral plasmid (Open Biosystems, Rockford, IL) were transfected into the PT67 amphotropic packaging cell line using lipofectamine (Invitrogen Corp.). Stable clonal cell lines producing p62 recombinant retrovirus at high titer (1×10^6 virus particles/ml) were established by selecting for resistance to neomycin (600 μg/ml). Similarly, a control retrovirus producer cell line was established by transfecting the cells with the pLXSN empty vector (EV). Producer cell lines were maintained in DMEM containing 10% fetal calf serum (FCS), 100 U/ml each of streptomycin and penicillin, 4 mM L-glutamine, and high glucose (4.5 g/liter). Retroviral supernatants from the producer cell cultures were collected and filtered (0.45 μm pore diameter) for immediate use. Mouse bone marrow-derived nonadherent cells were transduced with p62^{WT}, p62^{P392L}, or p62^{A381V} and CYLD shRNA retroviral supernatants (20%) from the producer cell lines in the presence of polybrene (4 μg/ml) for 24 h at 37 C in a 5% CO_2 incubator as described earlier (30).

OCL culture and bone resorption assay

Mouse bone marrow-derived nonadherent cells were dispersed into α-MEM containing 10% FCS and were seeded in 96-well plates at 6×10^5 cells/well in 0.2 ml of medium. Cells

FIG. 1. p62 interaction with CYLD. A, Site-directed mutagenesis of p62 non-UBA (p62^{A381V}) and UBA (p62^{P392L}) mutations associated with PDB. A plasmid containing the full-length human p62 cDNA was used as template for site-directed mutagenesis of UBA mutant, p62^{P392L} (C-to-T transition), and a non-UBA mutant, p62^{A381V} (C-to-T transition), as described in *Materials and Methods*. The mutagenized p62 cDNA sequenced to verify correct introduction of the P392L, A381V mutations as *circled*. B, p62 UBA mutation (p62^{P392L}) abolished interaction with CYLD in pre-OCL cells. Mouse bone marrow-derived nonadherent cells were transduced with retroviral expression plasmids of p62^{WT}, p62^{A381V}, or p62^{P392L}, and cells were stimulated with M-CSF (10 ng/ml) and RANKL (100 ng/ml) for 48 h. Total cell lysates obtained were subjected to immunoprecipitation using rabbit anti-HA antibody. The immunoprecipitants were analyzed by Western blotting using rabbit anti-CYLD antibody. The band intensity was quantified by National Institutes of Health ImageJ program, and CYLD immunoprecipitation was normalized with HA-tagged p62 expressed in these cells. The values are expressed as mean ± SD for three independent experiments (a, $P < 0.05$).

were transduced with p62^{WT}, p62^{A318V}, or p62^{P392L} and cultured in the presence of RANKL (100 ng/ml) and M-CSF (10 ng/ml) and were refed twice weekly by semidepletion (half of the medium withdrawn and replaced with fresh medium). At the end of culture period (5 d), the cells were fixed with 2% glutaraldehyde in PBS and stained for tartrate-resistant acid phosphatase (TRAP) activity using a histochemical kit (Sigma, St. Louis, MO). TRAP positive multinucleated cells containing three or more nuclei were scored as OCL cells under a microscope. Bone resorption activity of the OCL was assayed by culturing OCL for 10 d on dentine slices. At the end of the culture period, adherent cells were removed from the dentine disc, using 1 M NaOH and stained with 0.1% toluidine blue. The bone resorption area was quantified using computerized image analysis (Adobe Photoshop and Scion MicroImaging version 4.2). The percentage of the resorbed area was calculated relative to the total dentine disc area.

Coimmunoprecipitation assay

Mouse bone marrow-derived nonadherent cells were seeded in six-well plates (5×10^5 cells/well) were transduced with p62^{WT}, p62^{P392L}, or p62^{A381V} retroviral expression vectors and stimulated with M-CSF (10 ng/ml) and RANKL (100 ng/ml) for 48 h. Total cell lysates were collected in a lysis buffer [50 mM HEPES (pH 7.5), 250 mM NaCl, 0.2 mM EDTA, 10 μM NaF, and 0.5% Nonidet P-40] were immunoprecipitated using anti-HA antibody as described ear-

lier (29). Immunocomplexes were subjected to Western blot analysis for CYLD using rabbit anti-CYLD antibody.

Quantitative real-time RT-PCR

NFATc1 mRNA expression was measured by real-time RT-PCR as described previously (29). Briefly, total RNA was isolated from pre-OCL cells transfected with p62^{WT}, p62^{A381V}, or p62^{P392L} and were stimulated with and without RANKL (100 ng/ml) for 48 h, using RNAzol reagent (Biotecx Laboratories, Houston, TX). A RT reaction was performed using a cDNA synthesis kit (Bio-Rad, Hercules, CA) in a 25-μl reaction volume containing total RNA (2 μg), 1× PCR buffer, and 2 mM MgCl$_2$, at 42 C for 15 min followed by 95 C for 5 min. The quantitative real-time PCR was performed using IQ SYBR Green Supermix in an iCycler (iCycler iQ Single-color Real Time PCR Detection System; Bio-Rad). The primer sequences used to amplify glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were 5′-CCTA CCCCCAATGTATCCGTTGTG-3′ (sense) and 5′-GGAGGAATGGGAGTTGCTGTT GAA-3′ (antisense) and for mouse NFATc1 mRNA were 5′-GGCCGCAGAACACTAC AGTTA-3′ (sense) and 5′-GAGATACCCG GGGTGGAC-3′ (antisense). Thermal cycling parameters were 94 C for 3 min, followed by 40 cycles of amplifications at 94 C for 30 sec, 60 C for 1 min, 72 C for 1 min, and 72 C for 5 min as the final elongation step. Relative levels of NFATc1 mRNA expression were normalized in all the samples analyzed with respect to GAPDH amplification.

NF-κB, AP-1, and NFAT-Luc reporter gene assay

RAW 264.7 cells were cultured in DMEM supplemented with 10% FCS in a humidified atmosphere with 5% CO$_2$ at 37 C. DNA transfections were performed using lipofectamine transfection reagent (Invitrogen Corp.) according to the manufacturer's protocol. RAW 264.7 cells were transfected with NF-κB, AP-1, and NFAT-Luc reporter plasmids and coexpressed with p62^{WT}, p62^{P392L}, or p62^{A381V}. Cells were cultured in the presence or absence of RANKL (100 ng/ml) for 48 h. The cell monolayer was washed twice with PBS and incubated at room temperature for 15 min with 0.3 ml cell lysis buffer. The monolayer was scraped and spun briefly in a microfuge to pellet the debris. Then, a 20-μl aliquot of each sample was mixed with 100 μl of the luciferase assay reagent. Light emission was measured for 10 sec of integrated time using Sirius Luminometer (Promega). The transfection efficiency was normalized by cotransfection with 0.2 μg of pRSV β-gal plasmid and measuring β-galactosidase activity in the cell lysates. LacZ cytochemical activity staining (Invitrogen Corp.) indicated a DNA transfection efficiency (>80%) in RAW 264.7 cells.

TRAF6 ubiquitination assay

Mouse bone marrow-derived nonadherent cells were seeded in six-well plates (5×10^5 cells/well), transduced with p62^{WT},

p62^{P392L}, or p62^{A381V} retroviral expression vectors, and stimulated with M-CSF (10 ng/ml) and RANKL (100 ng/ml). After 48 h, total cell lysates were collected in a lysis buffer [50 mM HEPES (pH 7.5), 250 mM NaCl, 0.2 mM EDTA, 10 μM NaF, and 0.5% Nonidet P-40]. TRAF6 was immunoprecipitated using rabbit-anti-TRAF6 antibody, and the ubiquitin-conjugated TRAF6 was detected by Western blotting using rabbit-antiubiquitin antibody.

Statistical analysis

Results are presented as mean ± SD for three independent experiments and were compared by Student's t test. Values were considered significantly different for a and b, $P < 0.05$.

Results

p62^{P392L} UBA mutation (p62^{P392L}) abolished interaction with CYLD in pre-OCL cells

To examine the functional role of p62^{P392L} in OCL differentiation, we developed HA-tagged p62^{WT}, non-UBA mutant (p62^{A381V}), and UBA mutant (p62^{P392L}) retroviral expression vectors as described in *Materials and Methods*. Mouse bone marrow-derived nonadherent cells were transduced with p62^{WT}, p62^{A381V}, or p62^{P392L} expression vectors and stimulated with M-CSF (10 ng/ml) and RANKL (100 ng/ml) for 48 h. p62 was then immunoprecipitated from the total cell lysates using anti-HA antibody. Western blot analysis of the immunocomplex revealed that CYLD coimmunoprecipitated with p62^{WT} and non-UBA mutant p62^{A381V} but not with UBA mutant p62^{P392L}. In contrast, a control nonspecific rabbit IgG did not immunoprecipitate CYLD (Fig. 1B). These results suggest that the p62 UBA mutation (p62^{P392L}) abolished interaction with CYLD in pre-OCL cells.

p62^{P392L} enhances TRAF6 ubiquitination during OCL differentiation

TRAF6 is an adaptor molecule involved in RANK signaling, and polyubiquitination of TRAF6 plays an important role in OCL differentiation. To determine whether the p62^{P392L} mutant modulates TRAF6 ubiquitination during OCL differentiation, nonadherent mouse bone marrow cells were transduced with p62^{WT}, non-UBA mutant (p62^{A381V}), or UBA mutant (p62^{P392L}) and stimulated with RANKL (100 ng/ml) and M-CSF (10 ng/ml) for 48 h. Total cell lysates obtained were subjected to immunoprecipitation of TRAF6 using rabbit anti-TRAF6 antibody. Western blot analysis of the immunocomplexes using antiubiquitin antibody revealed accumulation of polyubiquitinated TRAF6 in p62^{P392L} transduced pre-OCL cells with and without RANKL stimulation compared with p62^{WT} and p62^{A381V} transduced cells. However, a modest increase in TRAF6 ubiquitination was observed in p62^{WT}

FIG. 2. p62^{P392L} enhance TRAF6 polyubiquitination during OCL differentiation. A, Mouse bone marrow-derived nonadherent cells were transduced with p62^{WT}, p62^{A381V}, or p62^{P392L}, and cells were stimulated with M-CSF (10 ng/ml) and RANKL (100 ng/ml) for 48 h. Cells transduced with EV served as control. B, shRNA knockdown of CYLD expression enhances TRAF6 polyubiquitination (Ub$_n$) in pre-OCL cells. Cells were transduced retroviral expression plasmids of p62^{WT}, p62^{A381V}, or p62^{P392L} with a nonspecific control shRNA and CYLD shRNA and stimulated with M-CSF (10 ng/ml) and RANKL (100 ng/ml) for 48 h. Total cell lysates obtained were subjected to immunoprecipitation using anti-TRAF6 antibody, and TRAF6 ubiquitination was analyzed by Western blotting using rabbit-antiubiquitin antibody. The band intensity was quantified by National Institutes of Health ImageJ program. The values are expressed as mean ± SD for three independent experiments (a and b, $P < 0.05$; compared with EV with and without RANKL stimulation, respectively).

and p62^{A381V} compared with control EV-transduced pre-OCL cells (Fig. 2A). We next examined whether shRNA suppression of CYLD in the presence of p62^{WT} and mutants modulate TRAF6 ubiquitination in pre-OCL cells. Mouse bone marrow-derived nonadherent cells were transduced with p62^{WT}, p62^{A381V}, or p62^{P392L} in the presence and absence of CYLD shRNA. Cells were stimulated with RANKL (100 ng/ml) and M-CSF (10 ng/ml) for 48 h, and total cell lysates obtained were subjected to immunoprecipitation of TRAF6. As shown in Fig. 2B, shRNA suppression of CYLD expression significantly increased polyubiquitination of TRAF6 in the presence of p62^{WT}, p62^{A381V}, and p62^{P392L} compared with nonspecific control shRNA transduced pre-OCL cells. These data suggests that p62^{P392L}/CYLD modulates TRAF6 ubiquitination during OCL differentiation.

p62^{P392L} modulation of downstream effectors of RANK signaling

p62^{P392L} has been shown to increase OCL differentiation (17, 20). Therefore, we examined whether p62^{P392L}/

CYLD modulates downstream effectors of RANK signaling during OCL differentiation. Mouse bone marrow-derived nonadherent cells were transduced with p62^{WT}, p62^{A381V}, or p62^{P392L} and stimulated with M-CSF (10 ng/ml) and RANKL (100 ng/ml) for different time points (0–60 min). Western blot analysis of total cell lysates obtained from pre-OCL cells revealed that p62^{P392L} induced high level expression of phospho-IκB with and without RANKL stimulation compared with p62^{WT} and p62^{P381V} transduced cells. However, we observed a modest increase in p-IκB expression in p62^{WT} and p62^{A381V} compared with EV transduced cells (Fig. 3A). Furthermore, pre-OCL cells stimulated with RANKL and M-CSF for 48 h had

increased (2.8-fold) c-Fos expression in p62^{P392L} compared with p62^{WT} or p62^{A381V} transduced cells (Fig. 3B). To further examine the role of p62^{P392L}/CYLD on c-Fos expression, mouse bone marrow-derived nonadherent cells were transduced with CYLD shRNA coexpressed with p62^{WT}, p62^{A381V}, or p62^{P392L} and stimulated with RANKL and M-CSF for 48 h. Western blot analysis of total cell lysates identified that CYLD knockdown significantly increased c-Fos expression in p62^{WT}, p62^{A381V}, or p62^{P392L} mutant transduced cells without RANKL stimulation compared with control shRNA transduced cells (Fig. 3C). shRNA suppression (~80%) of CYLD expression was confirmed by Western blot analysis (Fig. 3D).


FIG. 3. p62^{P392L} modulation of RANK signaling. Mouse bone marrow-derived nonadherent cells were transduced with p62^{WT}, p62^{A381V}, or p62^{P392L} and stimulated with M-CSF (10 ng/ml) and RANKL (100 ng/ml) for different time points (0–60 min). Cells transduced with EV served as control. A, Total cell lysates obtained from the pre-OCL cells were analyzed by Western blotting for p-IκB expression. B, Total cell lysates obtained from pre-OCL cells stimulated with M-CSF and RANKL for 48 h were analyzed by Western blotting for c-Fos expression. C, Mouse bone marrow-derived nonadherent cells were transduced with p62^{WT}, p62^{A381V}, or p62^{P392L} with presence of CYLD shRNA. Cells transduced with a nonspecific shRNA served as control. Cells were stimulated with M-CSF (10 ng/ml) and RANKL (100 ng/ml) for 48 h, and total cell lysates obtained were subjected to Western blot analysis of c-Fos expression. D, Western blot analysis of shRNA suppression of CYLD expression compared with nonspecific control shRNA. E, Total RNA isolated from pre-OCL cells transduced with p62^{WT}, p62^{A381V}, or p62^{P392L} and stimulated with RANKL and M-CSF for 48 h was subjected to real-time PCR analysis for NFATc1 mRNA expression and normalized with GAPDH mRNA amplification in these cells. The band intensity was quantified by National Institutes of Health ImageJ program, and values are expressed as mean ± SD for three independent experiments (a and, b $P < 0.05$; compared with EV with and without RANKL stimulation, respectively).

FIG. 4. A, $p62^{P392L}$ enhances NF-κB, AP-1 (B), and NFAT-Luc reporter gene activity (C). RAW 264.7 cells were transfected with NF-κB, AP-1, and NFAT- Luc reporter plasmids and coexpressed with $p62^{WT}$, $p62^{A381V}$, or $p62^{P392}$ and stimulated with and without RANKL (100 ng/ml) for 48 h. Total cell lysates prepared were assayed for luciferase activity. The transfection efficiency was normalized by β-galactosidase activity coexpressed in these cells. Values are expressed as mean ± SD for three independent experiments (a and b, $P < 0.05$; compared with EV with and without RANKL stimulation, respectively).

These results further suggest that $p62^{P392L}$ enhanced c-Fos gene expression during OCL differentiation. c-Fos plays an important role in expression of NFATc1, a critical transcription factor essential for OCL differentiation and bone resorption. Therefore, we next examined the functional impact of $p62^{P392L}$ in NFATc1 expression during OCL differentiation. Real-time PCR analysis of total RNA isolated from pre-OCL cells showed that $p62^{P392L}$ significantly increased (4.0-fold) NFATc1 mRNA expression without RANKL stimulation compared with $p62^{WT}$ or $p62^{A381V}$ transduced cells. In contrast, no significant changes in NFATc1 expression were observed in $p62^{WT}$ and $p62^{A381V}$ transduced cells compared with EV transduced cells (Fig. 3E).

To further confirm that p62 mutant modulates NF-κB, AP-1, and NFAT transcriptional activity, pNF-κB- Luc, AP-1-Luc, and NFAT-Luc reporter gene plasmids were transfected with $p62^{WT}$, $p62^{A381V}$, or $p62^{P392L}$ into RAW 264.7 cells and stimulated with RANKL (100 ng/ml) for 48 h. Total cell lysates obtained from these pre-OCL cells were analyzed for luciferase activity as described in *Materials and Methods*. Mutant $p62^{P392L}$ significantly increased NF-κB, AP-1, and NFAT reporter gene activity with and without RANKL stimulation compared with $p62^{WT}$ and $p62^{A381V}$ transfected cells. However, there was no significant change in the reporter gene activity with

$p62^{WT}$ and $p62^{A381V}$ mutant compared with control EV transfected cells (Fig. 4, A–C). These results suggest that the p62 UBA mutant ($p62^{P392L}$) stimulates downstream effectors of the RANK signaling pathway during OCL differentiation.

$p62^{P392L}$/CYLD shRNA increase OCL differentiation/bone resorption activity

To determine the potential of $p62^{P392L}$/CYLD shRNA to stimulate OCL formation, mouse bone marrow-derived nonadherent cells were transduced with CYLD shRNA coexpressed with $p62^{WT}$, $p62^{P392L}$, or $p62^{A381V}$ and cultured for OCL differentiation in the presence of RANKL (100 ng/ml) and M-CSF (10 ng/ml) for 5 d. Cells transduced with nonspecific shRNA served as control. The number of TRAP positive multinucleated OCL formed in these cultures was scored. $p62^{P392L}$ significantly increased OCL formation compared with control EV transduced cells. In contrast, no significant change in the rate of OCL formation was observed in $p62^{WT}$ and $p62^{A381V}$ transduced cells (Fig. 5A, *upper panel*). Furthermore, shRNA suppression of CYLD expression significantly increased OCL formation with $p62^{WT}$ and $p62^{A381V}$ similar to $p62^{P392L}$ compared with EV transduced cells (Fig. 5A, *lower panel*). shRNA knockdown of CYLD significantly increased OCL formation compared with nonspecific control shRNA transduced cells, which confirms that CYLD negatively regulates osteoclastogenesis (23). In addition, bone resorption activity of OCL was significantly increased with mutant $p62^{P392L}$ compared with $p62^{WT}$ and $p62^{A381V}$ transduced cells (Fig. 5B, *upper panel*). Also, shRNA suppression of CYLD expression significantly increased bone resorption activity in $p62^{WT}$ and $p62^{A381V}$ similar to mutant $p62^{P392L}$ compared with EV transduced cells (Fig. 5B, *lower panel*). Collectively, these results suggest that the p62 UBA mutation ($p62^{P392L}$) associated with PDB abolished interaction with CYLD, which promotes RANK signaling and increased OCL formation/bone resorption activity (Fig. 6).

Discussion

p62 has been shown to interact with the atypical protein kinase C and TRAF6 to modulate RANK signaling and

FIG. 6. Schematic illustration of p62^{P392L} mutant regulation of RANK signaling during OCL differentiation. p62^{P392L} mutation widely associated with PDB abolished interaction with CYLD, which promotes RANK signaling through enhanced TRAF6 ubiquitination, c-Fos, and NFATc1 gene expression (as indicated by *open arrows*), and thereby increases the OCL formation/bone resorption activity.

FIG. 5. p62^{P392L}/CYLD shRNA stimulation of OCL differentiation in mouse bone marrow cultures. A, Mouse bone marrow-derived nonadherent cells were transduced with CYLD shRNA and coexpressed with p62^{WT}, p62^{A381V}, or p62^{P392L}. Cells were stimulated with RANKL (100 ng/ml) and M-CSF (10 ng/ml) for 5 d, and the TRAP (+) multinucleated OCL formed in these cultures were scored. B, Bone resorption activity of OCL on dentine. The percentage of resorbed area on dentine was quantified as described in *Materials and Methods*. The results represent quadruplicate cultures of three independent experiments (a and b, $P < 0.05$; compared with EV with and without RANKL stimulation, respectively).

osteoclastogenesis (13). Ubiquitination of RANK adaptor protein, TRAF6, plays an important role in activation of NF-κB during OCL differentiation (31). The UBA domain truncated p62 has been shown to increase RANKL induced NFAT expression and ERK phosphorylation during osteoclastogenesis of RAW 264.7 cells (19). Deubiquitinating enzyme, CYLD, has been shown to inhibit NF-κB activation through deubiquitinatin of TRAF2 and TRAF6 (24). Furthermore, CYLD interacts with the p62 UBA domain to inhibit TRAF6 ubiquitination and negatively regulates RANK signaling and osteoclastogenesis (23). In the present study, we identify that in contrast to p62^{WT} and non-UBA mutant (p62^{A381V}), UBA mutant

(p62^{P392L}) abolished CYLD interaction, and this indicates that RANK signaling essential for osteoclastogenesis is modulated in PDB. We consistently observed accumulation of polyubiquitinated TRAF6 in p62^{P392L} transduced pre-OCL cells.

Ubiquitination of signaling molecules by E3 ubiquitin ligases has been shown to modulate NF-κB signaling (32). Because CYLD negatively regulates different signaling pathways by deubiquitination of K63-linked polyubiquitin chains from several substrates, it is possible that lack of p62^{P392L} interaction with CYLD may affect the ubiquitination status of other RANK signaling molecules that may also play a role in enhanced osteoclastogenesis. Elevated p-IκB expression in p62^{P392L} mutant transduced pre-OCL cells suggests p62^{P392L} activation of NF-κB in these cells. However, a modest increase observed in TRAF6 ubiquitination and p-IκB expression in p62^{WT} and p62^{A381V} compared with control EV transduced cells is more likely due to overexpression of p62 in these cells. Therefore, the mutant p62^{P392L} in contrast to p62^{WT} and p62^{A381V} stimulates NF-κB activity in pre-OCL cells, and this suggests that lack of p62^{P392L} interaction with CYLD may have a specific functional role in enhanced osteoclastogenesis in PDB. Previously, p62 has been shown to be involved in NF-κB activation (13). Further, p62^{P392L} mutation has been shown to elevate NF-κB activation as well as p38 MAPK and ERK1/2 signaling in OCL precursors stimulated with RANKL (17). However, Rea *et al.* (11) have shown that p62 wild type reduces and p62^{P392L} mutant

increases NF-κB activation in HEK293 and Cos-1 cells. Similarly, both p62 non-UBA (A381V) and UBA mutant (P392L) have been shown to increase NF-κB reporter gene activity in HEK293 cells (12). The variability in p62 regulation of NF-κB activity could be due to cell specificity and response to RANKL stimulation. p62 (440 amino acids) contains various domains that mediate protein-protein interactions (33). Several proteins that interact with p62 UBA domain, which includes calmodulin kinase II, nuclear receptor co-receptor I, heat shock protein 70, FK506 binding protein 14, homeobox protein Meis2, and Unc51 like kinase II, have been identified (21). In addition, p62 protein has been shown to interact with several signaling proteins, such as mitogen-activated protein kinases, atypical protein kinase C, p56^{lck}, receptor-interacting protein, TRAF6, ubiquitin, ubiquitinating, and deubiquitnating enzymes (33). Therefore, it is possible that p62^{A381V} may affect interaction with signaling molecules other than CYLD and modulates NF-κB activation in a cell-specific manner. Furthermore, our results that p62^{P392L} expression/shRNA knockdown of CYLD increased NF-κB, AP-1, and NFAT reporter gene activity indicate that mutant p62^{P392L} modulates NF-κB target gene expression required for enhanced osteoclastogenesis in PDB. This is further confirmed by the results that CYLD knockdown significantly increased c-Fos expression in p62^{WT}, p62^{A381V}, and p62^{P392L} mutant transduced cells without RANKL stimulation. Consistently, up-regulation of c-Fos gene expression in pagetic OCL and osteoblast cells has been reported (34). NFATc1 is a critical transcription factor for osteoclastogenesis (14), and our findings that p62^{P392L} up-regulated NFATc1 expression in pre-OCL cells favors increased osteoclastogenesis associated with PDB. Gene expression profiles in OCL revealed no significant change in p62 and CYLD expression in PDB (35). Inhibition of CYLD resulted in NF-κB activation and apoptotic resistance in hepatocellular carcinoma cells (36). Therefore, it is possible that the p62^{P392L} mutant may have a functional role in proliferation/survival of OCL progenitor cells, which have been shown to be increased in PDB (37). Also B-cell lymphoma 2, antiapoptotic gene expression has been shown to be up-regulated in pagetic bone (38). OCL formed in pagetic bone marrow cultures have high levels of IL-6 and TRAP activity (39). We identified that p62^{P392L} expression increased TRAP mRNA expression in pre-OCL cells (data not shown). p62^{P392L} modulation of c-Fos and NFATc1 expression implicated a potential role in enhanced osteoclatogenesis in PDB. Confirming this, we found that p62^{P392L} expression or shRNA knockdown of CYLD resulted in increased OCL formation and bone resorption activity in mouse bone marrow cultures. Therefore, lack of p62 UBA mutant interaction with CYLD results in increased OCL formation. Mutations in valosin-containing protein, which also contains the UBA domain, have been linked to inclusion body myopathy that is associated with PDB and frontotemporal dementia (IBMFD) (40). Valosin-containing protein is a multiubiquitin chain targeting factor for proteosome degradation, and it also plays an important role in regulating the NF-κB signaling cascade (41). Therefore, identification of p62^{P392L} regulated gene expression profiling is important to better understand the pathogenesis of PDB. Transgenic mice harboring p62^{P394L} mutation (equivalent to human p62^{P392L}) showed increase osteoclastogenic potential due to increased RANKL expression in marrow stromal cells in the bone microenvironment. The OCL precursors from these mice also demonstrated increased sensitivity to RANKL but not to 1,25 $(OH)_2D_3$ (42). Furthermore, p62 UBA mutant (p62^{P394L}) and MVNP coexpression in mice developed OCL with pagetic phenotype and increased IL-6 production (43). In contrast, others have recently shown that mice with p62^{P394L} mutation have focal lesions with increased OCL number, size, and some nuclear inclusions (18). Consistently, the OCL precursors from these mice are hypersensitive to RANKL. These studies have also suggested that p62^{P394L} mutation up-regulates autophagy, a cellular process for lysosomal degradation of damaged/dysfunctional organelles and protein aggregates (44). However, p62 null mice have a normal skeletal phenotype with no alterations were found in the trabecular size and number of OCL, suggesting that basal osteoclastogenesis is not affected by the loss of p62 (13). Therefore, p62 mutant protein-protein interactions play an important role in enhanced OCL development in PDB.

PDB patients with p62 mutations displayed polyostotic involvement, indicating severity of the disease (45, 46). However, the familial history of PDB is about 15–40% patients with a first degree relative and of which only 20–30% have a p62 mutation. Thus, p62 mutations occur in 5–10% of patients with PDB. Therefore, p62 mutant stimulation of OCL formation/bone resorption is associated with a very limited patient population. Recently, genome-wide association studies in individuals without p62 mutations have further identified genetic variants *CSF1*, *OPTN*, and *TNFRSF11A* as risk factors that predispose to PDB; however,, their functional role in pathogenesis of PDB is yet to be elucidated (47). Presence of nuclear inclusions in pagetic OCL suggested a viral etiology for PDB; however, no infectious virus is isolated. Despite the controversy about the identity of paramyxoviral nuclear inclusions and MVNP expression in pagetic OCL, it has been shown that targeted expression of MVNP to OCL lineage develops pagetic-like bone lesions in mice (48). Therefore, both genetic and environmental factors, such

as paramyxoviruses, play an important role in pathogenesis of PDB. In conclusions, p62 UBA mutation (p62^{P392L}) abolished interaction with CYLD and contributed to enhanced OCL development and excess bone resorption associated with PDB.

Acknowledgments

References

1. Morales-Piga AA, Rey-Rey JS, Corres-González J, García-Sagredo JM, López-Abente G 1995 Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res 10:663–670
2. Reddy SV 2004 Etiology of Paget's disease and osteoclast abnormalities. J Cell Biochem 93:688–696
3. Mills BG, Singer FR 1976 Nuclear inclusions in Paget's disease of bone. Science 194:201–202
4. Friedrichs WE, Reddy SV, Bruder JM, Cundy T, Cornish J, Singer FR, Roodman GD 2002 Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res 17:145–151
5. Merchant A, Smielewska M, Patel N, Akunowicz JD, Saria EA, Delaney JD, Leach RJ, Seton M, Hansen MF 2009 Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone. J Bone Miner Res 24:484–494
6. Mee AP, Dixon JA, Hoyland JA, Davies M, Selby PL, Mawer EB 1998 Detection of canine distemper virus in 100% of Paget's disease samples by in situ-reverse transcriptase-polymerase chain reaction. Bone 23:171–175
7. Helfrich MH, Hobson RP, Grabowski PS, Zurbriggen A, Cosby SL, Dickson GR, Fraser WD, Ooi CG, Selby PL, Crisp AJ, Wallace RG, Kahn S, Ralston SH 2000 A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 15:2315–2329
8. Matthews BG, Afzal MA, Minor PD, Bava U, Callon KE, Pitto RP, Cundy T, Cornish J, Reid IR, Naot D 2008 Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease. J Clin Endocrinol Metab 93:1398–1401
9. Seibenhener ML, Geetha T, Wooten MW 2007 Sequestosome 1/p62—more than just a scaffold. FEBS Lett 581:175–179
10. Hocking LJ, Lucas GJ, Daroszewska A, Mangion J, Olavesen M, Cundy T, Nicholson GC, Ward L, Bennett ST, Wuyts W, Van Hul W, Ralston SH 2002 Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 11:2735–2739
11. Rea SL, Walsh JP, Ward L, Yip K, Ward BK, Kent GN, Steer JH, Xu J, Ratajczak T 2006 A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-κB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res 21:1136–1145
12. Najat D, Garner T, Hagen T, Shaw B, Sheppard PW, Falchetti A, Marini F, Brandi ML, Long JE, Cavey JR, Searle MS, Layfield R 2009 Characterization of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone. J Bone Miner Res 24:632–642
13. Durán A, Serrano M, Leitges M, Flores JM, Picard S, Brown JP, Moscat J, Diaz-Meco MT 2004 The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6:303–309
14. Takayanagi H 2007 Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292–304
15. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF 2007 NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282:18245–18253
16. Teitelbaum SL, Ross FP 2003 Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649
17. Kurihara N, Hiruma Y, Zhou H, Subler MA, Dempster DW, Singer FR, Reddy SV, Gruber HE, Windle JJ, Roodman GD 2007 Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 117:133–142
18. Daroszewska A, van 't Hof RJ, Rojas JA, Layfield R, Landao-Basonga E, Rose L, Rose K, Ralston SH 2011 A point mutation in the ubiquitin associated domain of SQSMT1 is sufficient to cause a Paget's disease like disorder in mice. Hum Mol Genet 20:2734–2744
19. Yip KH, Feng H, Pavlos NJ, Zheng MH, Xu J 2006 p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-κB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget's disease of bone. Am J Pathol 169:503–514
20. Chamoux E, Couture J, Bisson M, Morissette J, Brown JP, Roux S 2009 The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. Mol Endocrinol 23:1668–1680
21. Pridgeon JW, Geetha T, Wooten MW 2003 A method to identify p62's UBA domain interacting proteins. Biol Proced Online 5:228–237
22. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S 2000 Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25:160–165
23. Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W, Wright A, Zhang M, You J, Sun SC 2008 Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 118:1858–1866
24. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G 2003 CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424:793–796
25. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R 2003 Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424:797–801
26. Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D, Courtois G 2003 The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424:801–805
27. Blake PW, Toro JR 2009 Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling. Hum Mutat 30:1025–1036

28. **Song L, Rape M** 2008 Reverse the curse—the role of deubiquitination in cell cycle control. Curr Opin Cell Biol 20:156–163

29. **Sundaram K, Senn J, Yuvaraj S, Rao DS, Reddy SV** 2009 FGF-2 stimulation of RANK ligand expression in Paget's disease of bone. Mol Endocrinol 23:1445–1454

30. **Shanmugarajan S, Youssef RF, Pati P, Ries WL, Rao DS, Reddy SV** 2008 Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity. J Cell Biochem 104:1500–1508

31. **Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J** 2001 Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20:1271–1280

32. **Harhaj EW, Dixit VM** 2011 Deubiquitinases in the regulation of NF-κB signaling. Cell Res 21:22–39

33. **Roodman GD, Windle JJ** 2005 Paget disease of bone. J Clin Invest 115:200–208

34. **Hoyland J, Sharpe PT** 1994 Upregulation of c-fos protooncogene expression in pagetic osteoclasts. J Bone Miner Res 9:1191–1194

35. **Michou L, Chamoux E, Couture J, Morissette J, Brown JP, Roux S** 2010 Gene expression profile in osteoclasts from patients with Paget's disease of bone. Bone 46:598–603

36. **Urbanik T, Köhler BC, Boger RJ, Wörns MA, Heeger S, Otto G, Hövelmeyer N, Galle PR, Schuchmann M, Waisman A, Schulze-Bergkamen H** 2011 Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol 38:121–131

37. **Demulder A, Takahashi S, Singer FR, Hosking DJ, Roodman GD** 1993 Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease. Endocrinology 133:1978–1982

38. **Brandwood CP, Hoyland JA, Hillarby MC, Berry JL, Davies M, Selby PL, Mee AP** 2003 Apoptotic gene expression in Paget's disease: a possible role for Bcl-2. J Pathol 201:504–512

39. **Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, Smith JF, Singer FR** 1992 Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 89:46–52

40. **Weihl CC, Pestronk A, Kimonis VE** 2009 Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. Neuromuscul Disord 19:308–315

41. **Custer SK, Neumann M, Lu H, Wright AC, Taylor JP** 2010 Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet 19:1741–1755

42. **Hiruma Y, Kurihara N, Subler MA, Zhou H, Boykin CS, Zhang H, Ishizuka S, Dempster DW, Roodman GD, Windle JJ** 2008 A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet 17:3708–3719

43. **Kurihara N, Hiruma Y, Yamana K, Michou L, Rousseau C, Morissette J, Galson DL, Teramachi J, Zhou H, Dempster DW, Windle JJ, Brown JP, Roodman GD** 2011 Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab 13:23–34

44. **Behrends C, Sowa ME, Gygi SP, Harper JW** 2010 Network organization of the human autophagy system. Nature 466:68–76

45. **Michou L, Morissette J, Gagnon ER, Marquis A, Dellabadia M, Brown JP, Siris ES** 2011 Novel SQSTM1 mutations in patients with Paget's disease of bone in an unrelated multiethnic American population. Bone 48:456–460

46. **Visconti MR, Langston AL, Alonso N, Goodman K, Selby PL, Fraser WD, Ralston SH** 2010 Mutations of SQSTM1 are associated with severity and clinical outcome in paget disease of bone. J Bone Miner Res 25:2368–2373

47. **Albagha OM, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie R, Dunlop MG, Fraser WD, Hooper MJ, Isaia G, Nicholson GC, del Pino Montes J, Gonzalez-Sarmiento R, di Stefano M, Tenesa A, Walsh JP, Ralston SH** 2010 Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet 42:520–524

48. **Kurihara N, Zhou H, Reddy SV, Garcia Palacios V, Subler MA, Dempster DW, Windle JJ, Roodman GD** 2006 Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J Bone Miner Res 21:446–455